ARCHIVES

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

This article is from The Cancer Letter archive.

Vol. 15 No. 04 | January 27, 1989

Download PDF Visit The Full Archive

Related Articles

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

Cancer Planners Revise Some Project Areas, Drop Some, Add New Ones

February 8, 1974

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

February 15, 2002

Top Management Shifts At Bristol-Myers Squibb Oncology, R&D Units

October 6, 1995

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

April 13, 2007

Tobacco Use Research Centers Funded

October 22, 1999